Loading...
Loading...
Addex Therapeutics Ltd.
Addex Therapeutics Ltd.. Spoken Alpha tracks ADXN's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks ADXN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ADXN.
curl https://api.spokenalpha.com/v1/companies/ADXN| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.61 | $2.17 | +20.4% | +1.9% | +2.7% |
| Q4 FY2026 | $2.56 | $2.21 | +15.9% | -7.8% | -9.6% |
| Q3 FY2026 | $2.71 | $2.34 | +15.7% | -4.0% | -2.9% |
| Q2 FY2026 | $2.80 | $2.19 | +27.7% | -0.9% | +0.2% |
| Q1 FY2025 | $2.99 | $2.30 | +29.9% | -7.3% | -9.6% |
| Q4 FY2025 | $3.00 | $2.34 | +28.4% | -6.2% | -4.5% |
| Q3 FY2025 | $3.03 | $2.45 | +23.8% | -3.9% | -3.0% |
| Q2 FY2025 | $2.80 | $2.26 | +24.0% | +3.1% | +2.2% |
| Q1 FY2024 | $2.87 | $2.48 | +15.6% | +0.3% | +0.1% |
| Q4 FY2024 | $2.86 | $2.47 | +15.6% | +2.6% | +2.7% |